Skip to main content

Table 4 Direct costs (SEK 2014) by GOLD state and type of event

From: Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

 

GOLD II

GOLD III

GOLD IV

No exacerbation

1284

3032

4297

Non-severe exacerbation

4423

6170

7436

Severe exacerbation

27,817

29,564

30,830

  1. Source: maintenance costs by GOLD-state from [5], exacerbation costs from [34]. Costs for mild and moderate exacerbations were merged to form non-severe exacerbations
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us